{"id":22014,"date":"2025-10-29T14:45:20","date_gmt":"2025-10-29T07:45:20","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=22014"},"modified":"2025-11-24T10:59:05","modified_gmt":"2025-11-24T03:59:05","slug":"zidovudine-and-lamivudine-tablets","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/zidovudine-and-lamivudine-tablets\/","title":{"rendered":"Zidovudine and Lamivudine Tablets"},"content":{"rendered":"

Action and use<\/strong><\/p>\n

Nucleoside reverse transcriptase inhibitor; antiviral (HIV).<\/p>\n

DEFINITION<\/h2>\n

Zidovudine and Lamivudine Tablets contain Zidovudine and Anhydrous Lamivudine.<\/p>\n

The tablets comply with the requirements stated under Tablets and with the following requirements.<\/p>\n

Content of zidovudine, C10<\/sub>H13<\/sub>N5<\/sub>O4<\/sub><\/h3>\n

95.0 to 105.0% of the stated amount.<\/p>\n

Content of lamivudine, C8<\/sub>H11<\/sub>N3<\/sub>O3<\/sub>S<\/h3>\n

95.0 to 105.0% of the stated amount.<\/p>\n

IDENTIFICATION<\/h2>\n

A. Carry out the method for thin-layer chromatography, Appendix III A, using the following solutions.<\/p>\n

(1) Shake a quantity of powdered tablets containing 0.1 g of Zidovudine with 50 mL of methanol, filter and use the filtrate.<\/p>\n

(2) 0.2% w\/v of zidovudine BPCRS in methanol.<\/p>\n

(3) 0.1% w\/v of lamivudine BPCRS in methanol.<\/p>\n

CHROMATOGRAPHIC CONDITIONS<\/h3>\n

(a) Use precoated silica gel F254 plates (Merck silica gel 60 F254 plates are suitable).<\/p>\n

(b) Use the mobile phase described below.<\/p>\n

(c) Apply 10 \u03bcL of each solution.<\/p>\n

(d) Develop the plate to 12 cm.<\/p>\n

(e) After removal of the plate, dry it in air and immediately examine under ultraviolet light (254 nm).<\/p>\n

MOBILE PHASE<\/h3>\n

3 volumes of glacial acetic acid, 10 volumes of methanol and 90 volumes of dichloromethane.<\/p>\n

SYSTEM SUITABILITY<\/h3>\n

The test is not valid unless the chromatogram obtained with solution (1) shows two clearly separated spots.<\/p>\n

CONFIRMATION<\/h3>\n

The chromatogram obtained with solution (1) shows two principal spots corresponding in position, colour and size to the principal spots in the chromatograms obtained with solutions (2) and (3).<\/p>\n

B. In the Assay, the chromatogram obtained with solution (1) shows principal peaks with the same retention times as the principal peaks due to zidovudine and lamivudine in the chromatograms obtained with solutions (2) and (3) respectively.<\/p>\n

TESTS<\/h2>\n

Dissolution<\/h3>\n

Comply with the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n

TEST CONDITIONS<\/h4>\n

(a) Use Apparatus 2 and rotate the paddle at 75 revolutions per minute.<\/p>\n

(b) Use 900 mL of 0.1M hydrochloric acid, at a temperature of 37\u00b0, as the medium.<\/p>\n

PROCEDURE<\/p>\n

Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n

(1) After 45 minutes withdraw a 10-mL sample of the medium and filter.<\/p>\n

(2) Dissolve suitable quantities of zidovudine BPCRS and lamivudine BPCRS in solvent A, described under Related substances, to produce the same concentrations as that expected for solution (1).<\/p>\n

(3) 0.01% w\/v of zidovudine and lamivudine impurity standard BPCRS in solvent A.<\/p>\n

CHROMATOGRAPHIC CONDITIONS<\/h4>\n

The chromatographic conditions described under Related substances may be used.<\/p>\n

DETERMINATION OF CONTENT<\/h4>\n

Calculate the total content of zidovudine, C10<\/sub>H13<\/sub>N5<\/sub>O4<\/sub>, and lamivudine, C8<\/sub>H11<\/sub>N3<\/sub>O3<\/sub>S, in the medium using the declared contents of C10<\/sub>H13<\/sub>N5<\/sub>O4<\/sub> in zidovudine BPCRS and of C8<\/sub>H11<\/sub>N3<\/sub>O3<\/sub>S in lamivudine BPCRS.<\/p>\n

LIMITS<\/h4>\n

The amounts of zidovudine and lamivudine released are not less than 75% (Q) of the stated amounts.<\/p>\n

Related substances<\/h3>\n

Carry out the method for liquid chromatography, Appendix III D, using the following solutions in solvent A.<\/p>\n

Solvent A Dissolve 1.9 g of ammonium acetate in 900 mL of water, adjust the pH to 4.0 with glacial acetic acid and dilute to 1000 mL. Mix 95 volumes of this solution with 5 volumes of methanol.<\/p>\n

(1) Shake a quantity of the powdered tablets containing 0.1 g of Zidovudine in 60 mL with the aid of ultrasound for 30 minutes, dilute to 100 mL and filter.<\/p>\n

(2) Dilute 1 volume of solution (1) to 100 volumes.<\/p>\n

(3) Dilute 1 volume of solution (2) to 10 volumes.<\/p>\n

(4) 0.002% w\/v of thymine.<\/p>\n

(5) 0.1% w\/v of zidovudine and lamivudine impurity standard BPCRS.<\/p>\n

(6) Dilute 1 volume of solution (3) to 2 volumes.<\/p>\n

CHROMATOGRAPHIC CONDITIONS<\/h4>\n

(a) Use a stainless steel column (25 cm \u00d7 4.6 mm) packed with octadecylsilyl silica gel for chromatography (5 \u03bcm) (YMC ODS-A is suitable).<\/p>\n

(b) Use gradient elution and the mobile phase described below.<\/p>\n

(c) Use a flow rate of 0.7 mL per minute.<\/p>\n

(d) Use a column temperature of 30\u00b0.<\/p>\n

(e) Use a detection wavelength of 270 nm.<\/p>\n

(f) Inject 20 \u03bcL of each solution.<\/p>\n

MOBILE PHASE<\/h4>\n

Mobile phase A: 0.025M ammonium acetate, the pH adjusted to 4.0 with glacial acetic acid.<\/p>\n

Mobile phase B: methanol.<\/p>\n

Mobile phase C: acetonitrile.<\/p>\n\n\n\n\n\n\n\n\n\n\n
Time (Minutes)<\/strong><\/td>\nMobile phase A (% v\/v)\u00a0<\/strong><\/td>\nMobile phase B (% v\/v)\u00a0<\/strong><\/td>\nMobile phase C (% v\/v) <\/strong><\/td>\nComment<\/strong><\/td>\n<\/tr>\n
0-15<\/td>\n95<\/td>\n5<\/td>\n0<\/td>\nisocratic<\/td>\n<\/tr>\n
15-30<\/td>\n95\u219270<\/td>\n5\u219230<\/td>\n0<\/td>\nlinear gradient<\/td>\n<\/tr>\n
30-38<\/td>\n70<\/td>\n30<\/td>\n0<\/td>\nisocratic<\/td>\n<\/tr>\n
38-39<\/td>\n70\u21920<\/td>\n30\u21920<\/td>\n0\u2192100<\/td>\nchange of solvent<\/td>\n<\/tr>\n
39-45<\/td>\n0<\/td>\n0<\/td>\n100<\/td>\nwashing column<\/td>\n<\/tr>\n
45-46<\/td>\n0\u219295<\/td>\n0\u21925<\/td>\n100\u21920<\/td>\nchange of solvent<\/td>\n<\/tr>\n
46-60<\/td>\n95<\/td>\n5<\/td>\n0<\/td>\nre-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SYSTEM SUITABILITY<\/h4>\n

The test is not valid unless: the chromatogram obtained with solution (5) closely resembles the reference chromatogram supplied with zidovudine and lamivudine impurity standard BPCRS; the resolution between the peaks due to lamivudine impurity B and lamivudine is at least 2.0; the resolution between the peaks due to lamivudine and thymidine is at least 2.0; the resolution between the peaks due to zidovudine and zidovudine impurity B is at least 4.0.<\/p>\n

LIMITS<\/h4>\n

Using the chromatogram obtained with solution (5) and the reference chromatogram supplied with zidovudine and lamivudine impurity standard BPCRS identify any peaks in solution (1) corresponding to the named lamivudine and zidovudine impurities.<\/p>\n

In the chromatogram obtained with solution (1):<\/p>\n

the area of any peak corresponding to thymine (zidovudine impurity C) is not greater than the area of the principal peak in<\/p>\n

the chromatogram obtained with solution (4) (2.0%);<\/p>\n

the area of any peak corresponding to zidovudine impurity B is not greater than the area of the peak due to zidovudine in<\/p>\n

the chromatogram obtained with solution (2) (1.0%);<\/p>\n

the area of any peak corresponding to zidovudine impurity G (the retention relative to zidovudine is about 1.4) is not greater than 0.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.5%);<\/p>\n

the area of any peak corresponding to lamivudine impurity A is not greater than 3 times the area of the peak due to lamivudine in the chromatogram obtained with solution (3) (0.3%);<\/p>\n

the area of any other secondary peak is not greater than twice the area of the peak due to zidovudine in the chromatogram obtained with solution (3) (0.2%);<\/p>\n

the sum of the areas of all secondary peaks is not greater than 5.2 times the area of the peak due to zidovudine in the chromatogram obtained with solution (2) (5.2%).<\/p>\n

Disregard any peak with an area less than the area of the peak due to zidovudine in the chromatogram obtained with solution (6) (0.05%).<\/p>\n

ASSAY<\/h2>\n

Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, using the following solutions dissolved in solvent A described under Related substances.<\/p>\n

(1) Shake a quantity of the powdered tablets containing 0.1 g of Zidovudine with 50 mL of solvent A in a 100 mL amber volumetric flask for 30 minutes, dilute to 100 mL and filter. Dilute 1 volume to 5 volumes.<\/p>\n

(2) 0.02% w\/v of zidovudine BPCRS.<\/p>\n

(3) 0.01% w\/v of lamivudine BPCRS.<\/p>\n

(4) 0.1% w\/v of zidovudine and lamivudine impurity standard BPCRS.<\/p>\n

CHROMATOGRAPHIC CONDITIONS<\/h3>\n

The chromatographic conditions described under Related substances may be used.<\/p>\n

SYSTEM SUITABILITY<\/h3>\n

The test is not valid unless, in the chromatogram obtained with solution (4): the resolution between the peaks due to lamivudine impurity B and lamivudine is at least 2.0; the resolution between the peaks due to lamivudine and thymidine is at least 2.0; the resolution between the peaks due to zidovudine and zidovudine impurity B is at least 4.0.<\/p>\n

DETERMINATION OF CONTENT<\/h3>\n

Using solutions (1) and (2), calculate the total content of C10<\/sub>H13<\/sub>N5<\/sub>O4<\/sub> in the tablets from the chromatograms obtained using the declared content of C10<\/sub>H13<\/sub>N5<\/sub>O4<\/sub> in zidovudine BPCRS.<\/p>\n

Using solutions (1) and (3) calculate the total content C8<\/sub>H11<\/sub>N3<\/sub>O3<\/sub>S in the tablets from the chromatograms obtained using the declared content of C8<\/sub>H11<\/sub>N3<\/sub>O3<\/sub>S in lamivudine BPCRS.<\/p>\n

IMPURITIES<\/h2>\n

The impurities limited by the requirements of this monograph include those listed separately under Zidovudine and Anhydrous Lamivudine respectively.<\/p>\n","protected":false},"excerpt":{"rendered":"

Action and use Nucleoside reverse transcriptase inhibitor; antiviral (HIV). DEFINITION Zidovudine and Lamivudine Tablets contain Zidovudine and Anhydrous Lamivudine. The tablets comply with the requirements stated under Tablets and with the following requirements. Content of zidovudine, C10H13N5O4 95.0 to 105.0% of the stated amount. Content of lamivudine, C8H11N3O3S 95.0 to 105.0% of the stated amount….<\/p>\n","protected":false},"author":4,"featured_media":22021,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-22014","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/22014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=22014"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/22014\/revisions"}],"predecessor-version":[{"id":22023,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/22014\/revisions\/22023"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/22021"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=22014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=22014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=22014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}